目的:探讨联合化疗方案治疗晚期原发性肝癌患者的有效性与安全性.方法:31例晚期原发性肝癌患者,采用奥沙利铂(L-OHP)、吡柔比星(THP)、氟尿嘧啶(5-FU)组成的联合方案进行化疗,观察和评价其疗效及毒副反应.结果:31例患者中,获得CR 0例,PR 9例,SD 14例,PD 8例,疾病控制率(DCR)74.2％；中位肿瘤进展时间(TTP) 4.2月；中位生存期(OS)为10.2月；临床受益反应(CBR)率达77.4％；化疗后的血清AFP值较前明显下降.主要的毒副反应为骨髓抑制、消化道反应和感觉神经毒性.结论:奥沙利铂、吡柔比星、氟尿嘧啶组成的联合方案治疗晚期原发性肝癌的疗效安全可靠,不良反应可以接受.%Objective:To assess the efficiency and safety of systemic chemotherapy in the patients with histologi-cally confirmed recurrent, metastatic, or unresectable hepatocellular carcinoma ( HCC). Methods: Thirty one patients with advanced HCC were given systemic chemotherapy(THP 35mg/m2 iv d1;L - OHP 100 - 130mg/m2 ivgtt d, ;CF 200mg/m2 ivgtt d1-5 ;5 - FU 400mg/m2 iv d1 _2,600mg/m2 civ 22h d1-2;or CF 400mg/m2 ivgtt d1 ;5 - FU 400mg/ m2 iv d1 ,2400mg/m2 civ 46h,repeated every 3-4 weeks). Tumor response,time to progression,survival,and toxicity were evaluated. Results: None of the patients had a complete response to treatment,9 patients obtained partial response, 14 patients stable disease,8 patients disease progression; Median time to tumor progression (TTP) was 4.2 months, median overall survival ( OS) 10.2 months. Compared to pre - treatment, there was a significant decrease of serum AFP level. The main toxic side effects included hematologic toxicity, alimentray tract reaction and neurotoxicity. Conclusion: The systemic chemotherapy regimen combined L - OHP, THP and 5 — FU is a safe and effective therapy for patients with advanced HCC. All the adverse effects were well tolerable.
展开▼
